Research Journal of Medical Sciences
ISSN: Online 1993-6095ISSN: Print 1815-9346
Abstract
The Covid vaccine pandemic of 2019 saw a surge in the production and marketing of various vaccines across the world such as Pfizer‐BioNTech, Moderna, Janssen and Janssen etc that were rolled out in order to boost immunity. Two of the foremost vaccines that were marketed in India were the Covaxin by Bharat Biotech, a whole virion inactivated vaccine and the Covishield, a recombinant adenovirus vector vaccine, manufactured by the Serum institute of India. The major adverse effects that were reported with these vaccines include injection site pain, fever, myalgia, nausea, diarrhoea and giddiness. Although many serious and potentially life‐threatening adverse effects following immunisation (AEFIs) have been reported with mRNA vaccines, such as Guillane Barre syndrome, myocarditis, pericarditis and thrombocytopenia, no such literature exists as to the safety profile of Covishield vaccine. This report aims to discuss the incidence of a sudden‐onset ipsilateral cervical lymphadenopathy in a 31 year old male health care worker, with previous history of Tb, working in a teaching hospital in India, following inoculation with the second dose of Covishield vaccine. Relevant history ‐taking and investigations including imaging, cytology and microbiological examination were done to establish the causality of the case and rule out other differentials, namely Tb and malignancy. This is the first such reported case of cervical adenopathy following Covishield vaccination and highlights the need for prompt adverse event reporting and management in any presentation with a neck lump.
How to cite this article:
Moumita Chakraborty, Ajit Pratap Singh, Sanjay Gedam and Pushpendra Singh Kanwar. Covishield‐Induced Cervical Lymphadenopathy in a Case of Latent TB Infection: A Case Report.
DOI: https://doi.org/10.36478/10.59218/makrjms.2023.693.698
URL: https://www.makhillpublications.co/view-article/1815-9346/10.59218/makrjms.2023.693.698